{"id":"W4388588971","doi":"10.1093/neuonc/noad179.0259","title":"CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Toronto Western Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical endpoint; Medicine; Pembrolizumab; Oncolytic virus; Oncology; Internal medicine; Hazard ratio; Confidence interval; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001551532,0.001387698,0.00145937,0.0003842549,0.0002970004,0.000684489,0.0005652981,0.0008304873,0.001728667],"category_scores_gemma":[0.0004029069,0.0004001004,0.0009097709,0.000317121,0.0006253634,0.0005457836,0.0002875334,0.001997151,0.0004497791],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007166243,"about_ca_system_score_gemma":0.0008943016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008561837,"about_ca_topic_score_gemma":0.00173827,"domain_scores_codex":[0.999648,0.0001731336,0.00001954994,0.00006085194,0.00003449818,0.0000640867],"domain_scores_gemma":[0.9997675,0.00002655443,0.00005524715,0.00002140267,0.00001980626,0.0001094379],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6633105,0.05483624,0.004427591,0.001583576,0.00259534,0.0004354398,0.0003174866,0.004668481,0.09618391,0.0005466409,0.006023169,0.1650716],"study_design_scores_gemma":[0.449717,0.5233904,0.008162804,0.00006647061,0.0008309303,0.0003663475,0.00006304267,0.003179295,0.01014355,0.0002873805,0.00375133,0.00004144478],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931859,0.003326354,0.0005312326,0.0003310919,0.0001521225,0.00117194,0.0004039159,0.0000754577,0.0008220332],"genre_scores_gemma":[0.9915646,0.002401151,0.00130551,0.000531077,0.0001825017,0.00134709,0.0009459842,0.00002863224,0.001693343],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001728667,"threshold_uncertainty_score":0.008205414,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03965479245783439,"score_gpt":0.3864301045020404,"score_spread":0.346775312044206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}